Vanda Pharmaceuticals Inc VNDA

NAS: VNDA | ISIN: US9216591084 18/03/2026

8,560 USD (-0,47%)

(-0,47%) 18/03/2026

Grafiek Vanda Pharmaceuticals Inc

Grafiek Vanda Pharmaceuticals Inc

1 dag1d -0,47%
1 week1w -7,86%
1 maand1m 40,33%
3 maanden3m 26,81%
6 maanden6m 90,65%
1 jaar1j 73,28%
5 jaar5j -51,00%

Vanda Pharmaceuticals Inc in het nieuws

Toon enkel gratis nieuws

3 maart 2026 · Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years · Persbericht

26 februari 2026 · Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference · Persbericht

25 februari 2026 · Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis · Persbericht

20 februari 2026 · Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation · Persbericht

11 februari 2026 · Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results · Persbericht

5 februari 2026 · Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 · Persbericht

8 januari 2026 · Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder · Persbericht

31 december 2025 · Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness · Persbericht

15 december 2025 · Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis · Persbericht

11 december 2025 · Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference · Persbericht

Profiel Vanda Pharmaceuticals Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.vandapharma.com

Hoofdzetel: Washington, Washington Dc Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe